Mixed-cell complement lysis: simulation study
Study RBC population . | Sensitization* . | 6% albumin IgM . | Anti-human IgG . | Complement-mediated lysis† . | Anti-human C3b/d . |
---|---|---|---|---|---|
20% AET-treated | Group O plasma | W | 2+s | Weak hemolysis | 0 |
Pooled AB plasma | 0 | 0 | No hemolysis | 0 | |
PNH sample (9%) | Anti-I | 1+ | 2+ | Hemolysis | 1+ |
Pooled AB plasma | 0 | 0 | No hemolysis | 0 |
Study RBC population . | Sensitization* . | 6% albumin IgM . | Anti-human IgG . | Complement-mediated lysis† . | Anti-human C3b/d . |
---|---|---|---|---|---|
20% AET-treated | Group O plasma | W | 2+s | Weak hemolysis | 0 |
Pooled AB plasma | 0 | 0 | No hemolysis | 0 | |
PNH sample (9%) | Anti-I | 1+ | 2+ | Hemolysis | 1+ |
Pooled AB plasma | 0 | 0 | No hemolysis | 0 |
Hemagglutination and hemolysis were scored according to Judd et al20 : 0, negative reaction, no agglutination; W, weak reaction, many tiny agglutinates; 1+, very small just visible agglutinates; 2+, many small visible agglutinates; 2+s, medium sized visible agglutinates.
†Presence of hemolysis visualized after incubation with AB serum at 37°C for 60 min.